Scaling back new services related to COVID-19 and other areas
First written in FY2024-Q1. 2 of 5 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「While revenue from COVID-19-related and other services, including in-home clinical trials and health-monitoring support, declined, total cumulative care hours during the current interim consolidated accounting period reached 607 thousand hours, up 16.5% year on year, as the number of users and care hours per user increased,」
The decline in COVID-19-related service revenue continued, while expansion of existing home-visit nursing services offset part of the impact. - FY2024WorsenedAnnual report
「These COVID-19-related and other services contracted substantially during the current consolidated fiscal year, but they are presented separately below from existing services to facilitate comparison with the previous consolidated fiscal year.」
Revenue from COVID-19-related and other services fell 95.3% year on year, and the label was changed from “new services” to “COVID-19-related and other services.” - FY2024-Q3WorsenedAnnual report
「These new services contracted substantially during the first 3 quarters of the current consolidated cumulative period, but they are presented separately below from existing services to facilitate comparison with the first 3 quarters of the previous consolidated fiscal year.」
The contraction of COVID-19 vaccination support, in-home clinical trials and health-monitoring support progressed further, with new-service revenue down 94.9% year on year. - FY2024-Q2RestatedAnnual report
「These new services contracted substantially during the first 2 quarters of the current consolidated cumulative period, but they are presented separately below from existing services to facilitate comparison with the first 2 quarters of the previous consolidated fiscal year.」
The contraction of COVID-19 vaccination support, in-home clinical trials and health-monitoring support continued, with new-service revenue down 93.9% year on year. - FY2024-Q1MaterialisedAnnual report
「We define the COVID-19 vaccination support service in the healthcare institution support segment and the in-home clinical trial and health-monitoring support services in the home-visit nursing segment, which began in the consolidated fiscal year before last, as new services. These new services contracted substantially during the first quarter of the current consolidated cumulative period.」
Revenue from new services fell 94.0% year on year, and the contraction has become an actual factor behind the group’s revenue decline.